Background-Fibrinogen is both central to blood coagulation and an acute-phase reactant. We aimed to identify common variants influencing circulation fibrinogen levels.
E levated levels of fibrinogen within or above the normal range are consistently associated with an increased risk of cardiovascular disease. 1 Fibrinogen has a key role in blood coagulation but is also known as a marker of inflammation. Studies in persons of European ancestry have estimated the heritability of multivariable-adjusted fibrinogen levels from 24% in multiplex families 2 to Ͼ50% in twins. 3 The 3 genes encoding the 3 fibrinogen protein chains explain only a small part of the total estimated genetic variance of circulating levels of fibrinogen. 4 
Clinical Perspective see p 133
The objective of this study was to identify novel genetic loci related to plasma fibrinogen levels. A meta-analysis of genome-wide association (GWA) findings was conducted on 6 population-based studies. We analyzed GWA data of 2 661 766 single-nucleotide polymorphisms (SNPs) from 1 or more studies from a total of 22 096 participants of European descent.
Methods
The setting for this meta-analysis is primarily the Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium. 5 
The Rotterdam Study
The RS is a prospective, population-based cohort study of determinants of several chronic diseases in older adults. 6 In brief, the study comprised 7983 inhabitants of Ommoord, a district of Rotterdam in the Netherlands, who were 55 years or older. The baseline examination took place between 1990 and 1993.
Genotyping was conducted using the Illumina 550K array. SNPs were excluded for minor allele frequency (MAF) Յ1%, Hardy-Weinberg equilibrium (HWE) PϽ10 Ϫ5 , or SNP call rate Յ90%, resulting in data on 530 683 SNPs. Imputation was done with reference to HapMap release 22 CEU using the maximum likelihood method implemented in MACH (http://www.sph.umich.edu/csg/ abecasis/MACH/index.html). The final population for this fibrinogen analysis comprised 2068 individuals.
Framingham Heart Study
The FHS started in 1948 with 5209 randomly ascertained participants from Framingham, Mass, who had undergone biannual examinations to investigate cardiovascular disease and its risk factors. 7 In 1971, the offspring cohort 8, 9 (comprised of 5124 children of the original cohort and the children's spouses) and in 2002, the third generation (consisting of 4095 children of the offspring cohort), were recruited. 10 FHS participants in this study are of European ancestry.
Genotyping was carried out as a part of the SNP Health Association Resource project using the Affymetrix 500K mapping array (250K Nsp and 250K Sty arrays) and the Affymetrix 50K supplemental gene focused array on 9274 individuals. Genotyping resulted in 503 551 SNPs with successful call rate Ͼ95% and HWE PϾ10 Ϫ6 on 8481 individuals with call rate Ͼ97%. Imputation of Ϸ2.5 million autosomal SNPs in HapMap with reference to release 22 CEU sample was conducted using the algorithm implemented in MACH. The final population for fibrinogen analysis included 7022 individuals (original cohort, nϭ383; offspring, nϭ2806; third generation, nϭ3833).
Cardiovascular Health Study
The CHS is a population-based, observational study of risk factors for clinical and subclinical cardiovascular diseases. 11 The study recruited participants 65 years and older from 4 US communities in 2 phases: 5201 participants from 1989 to 1990, and 687 (primarily black participants) from 1992 to 1993. A GWA study was conducted in a subset of CHS participants (nϭ3980), all of whom were without clinical cardiovascular disease at their baseline clinical visit and provided consent to use their DNA for research. The study sample used in the fibrinogen analysis represented the first 2 of 3 rounds of genotyping, which was a stratified probability sample. Weights were assigned to each observation to reflect the likelihood of sampling from the 3980 participants. The analysis was restricted to participants of European decent.
Genotyping was performed using the Illumina 370 CNV BeadChip system. Samples were excluded for sex mismatch, discordance with previous genotyping, or call rate Ͻ95%. SNPs were excluded from the analysis when monomorphic, when HWE PϽ10 Ϫ5 , and when call rates were Ͻ95%. Imputation was performed using BIMBAM (version 0.95; http://stephenslab.uchicago.edu/software.html) with reference to Hap-Map CEU using release 21A. The population available for the fibrinogen analysis included 1993 individuals.
Atherosclerosis Risk in Communities Study
The ARIC study is a longitudinal cohort study of atherosclerosis and its clinical sequelae. It recruited a population-based sample of 15 792 men and women aged 45 to 64 years from 4 US communities from 1987 to 1989. 12 The analysis was restricted to subjects of European decent.
Genotyping was performed using the Affymetrix Genome-Wide Human SNP Array 6.0. SNPs were excluded for not being autosomal SNPs, not passing laboratory quality checking, no chromosome location, MAFՅ1%, SNP call rate Ͻ90%, or HWE PϽ10 Ϫ6 . This resulted in data on 716 442 SNPs. Imputation to HapMap SNPs was performed using MACH. After excluding subjects who disallowed DNA use, subjects with a mismatch between called and phenotypic sex, with a mismatch on Ͼ10 of 47 previously analyzed SNPs in ARIC, all but 1 in sets of first-degree relatives, and other individuals who were genetic outliers, the final population for fibrinogen analysis comprised 8051 individuals.
MONICA/KORA
The presented data were derived from the third population-based MONICA/KORA survey S3. 13 This cross-sectional survey covering the city of Augsburg (Germany) and 2 adjacent counties was conducted in 1994/1995 to estimate the prevalence and distribution of cardiovascular risk factors among individuals aged 25 to 74 years as part of the World Health Organization MONICA study. The MONICA/KORA S3 study comprises 4856 subjects. Among them, 3006 subjects participated in a follow-up examination of S3 in 2004/2005 (MONICA/KORA F3). All participants underwent standardized examinations including blood withdrawals for plasma and DNA. For the KORA GWA study, 1644 subjects aged 45 to 69 years were selected from the KORA S3/F3 samples.
Genotyping was performed using the Affymetrix 500K Array Set. Samples were excluded for sex mismatch, discordance with previous genotyping, or call rate Ͻ95%. SNPs were excluded from the analysis when monomorphic (MAFϽ0.01), when call rates per SNP were Ͻ0.1, and per individual were Ͻ0.1. Imputation was done using maximum likelihood method implemented in MACH 1.0. The final population available for the fibrinogen analysis included 1523 individuals.
British 1958 Birth Cohort
The British 1958 Birth Cohort is a national population sample followed periodically from birth. At age 44 to 45 years, 9377 cohort members were examined by a research nurse in the home as described previously. 14 For this study, we used a total of 1480 cell-line-derived DNA samples from unrelated subjects of European ancestry, with nationwide geographic coverage, which were used as controls by the Wellcome Trust Case Control Consortium. 15 Genotyping was performed using the Affymetrix 500K Mapping Array Set using the call algorithm Chiamo (http://www.stats.ox. ac.uk/ϳmarchini/software/gwas/chiamo.html), as implemented by the Wellcome Trust Case Control Consortium. 15 Genotypes at other loci were imputed by the program IMPUTE (version 0. 
Measurement of Fibrinogen
In the KORA study, fibrinogen was determined by an immunonephelometric method (Dade Behring Marburg GmbH, Marburg, Germany) on a Behring Nephelometer II analyzer. FHS study used the Clauss method 16 in the offspring and the third-generation subjects, and a modified method of Ratnoff and Menzie 17 in the original cohort subjects. In the RS, fibrinogen levels were derived from the clotting curve of the prothrombin time assay using Thromborel S as a reagent on an automated coagulation laboratory 300 (ACL 300, Instrumentation Laboratory, Zaventem, Belgium). The other studies used the Clauss method for measuring plasma fibrinogen. 16 
Statistical Analysis
Each study independently analyzed their genotype-phenotype data. Except for FHS, which has a family structure, all studies conducted analyses of all directly genotyped and imputed SNPs using linear regression on untransformed fibrinogen measures using an additive genetic model adjusted for age, sex, and site of recruitment (if necessary). In FHS, a linear mixed effects model was used with a fixed additive effect for the SNP genotype, fixed covariate effects, random family-specific additive residual polygenic effects to account for within family correlations, 18 and a random environment effect. In addition, FHS adjusted for population stratification using principal components of the directly measured SNPs, which were computed using the Eigenstrat software (http://genepath.med.harvard.edu/ Ϸreich/eigentrat.htm).
To account for residual stratification, P values were adjusted for genomic inflation. The inflation of the association test statistic, stated as inflation factor lambda (gc), was small for all studies: 0.995 for RS, 1.016 for FHS, 1.031 for CHS, 1.024 for ARIC, 1.012 for KORA, and 1.008 for British 1958 Birth Cohort. Using the studyspecific results, we conducted a fixed effect model meta-analysis based on inverse-variance weighting. MetABEL (http://mga.bionet. nsc.ru/Ϸyurii/ABEL), a package running under R (http://www.rproject.org), was used to perform the meta-analysis. We used Bonferroni correction to deal with the problem of multiple testing. Simulation studies show that the effective number of independent tests in a GWA analysis is nearly 1 million. 19 On the basis of 1 million tests, we selected a P value threshold of 5ϫ10 Ϫ8 as the level of genome-wide significance.
In addition, we estimated the effect of the top SNPs in strata of sex and smoking status. Gene-by-sex and gene-by-smoking interactions were tested in each study by introducing an interaction term into the linear model. We used a sample size weighted meta-analysis to combine the reported interaction P values across studies for each of the top SNPs.
Replication in Women's Health Genome Study
We used the Women's Health Genome Study (WHGS) to replicate our genome-wide significant findings and other loci for which our meta-analysis generated more modest evidence of an association (P value of 5ϫ10 Ϫ7 ). Participants in WHGS are derived from the genetic arm of the Women's Health Study and include American women with no previous history of cardiovascular disease, cancer, or other major chronic illness who provided a baseline blood sample during the enrollment phase of the Women's Health Study between 1992 and 1995. 20 Fibrinogen levels were measured using an immunoturbidimetric assay (Kamiya Biomedical, Seattle, Wash), which was standardized to a calibrator from the World Health Organization. Genotyping was done using the Illumina Infinium II assay to query a genome-wide set of 315 176 haplotype-tagging SNP markers (Human HAP300 panel) as well as a focused panel of 45 882 missense and haplotype tagging SNPs. For this analysis, the evaluation was performed on 17 686 nondiabetic individuals who were of white ancestry and were not taking lipid-lowering agents. The GWA results of the WHGS are reported in a companion manuscript.
Results
The sample size and participant characteristics from each study are shown in Table 1 . A quantile-quantile plot of the observed against expected P value distribution is shown in Figure 1 . Figure 2 illustrates the primary findings from the (Figure 3 ). The strongest statistical evidence for an association was for rs1800789, which is located at 4q31.3 in exon 7 of the fibrinogen ß (FGB) gene (MAF: 0.20 to 0.24, meta-analysis Pϭ1.75ϫ10 Ϫ30 , fibrinogen level change per minor allele [⌬]: 0.087 g/L). The other significant loci were marked by rs2522056, which is located at 5q23.3, 25-kb downstream of the interferon regulatory factor 1 (IRF1) gene (MAF: 0.17 to 0.21, Pϭ1.3ϫ10 Ϫ15 , ⌬: Ϫ0.063 g/L), rs511154, which is located at 3q22.3, in intron 1 of the propionyl coenzyme A carboxylase, ␤-polypeptide (PCCB) gene (MAF: 0.21 to 0.24, Pϭ5.94ϫ10 Ϫ10 , ⌬: 0.045 g/L), and rs1539019 that is located at 1q44, on the NLR family, pyrin domain containing 3 isoforms (NLRP3) gene (MAF: 0.37 to 0.42, Pϭ1.04ϫ10 Ϫ8 , ⌬: Ϫ0.038 g/L). Cohort-specific findings are presented for the top SNP within each locus in Table 2 . Results did not change materially when we adjusted the model for other covariates (smoking, alcohol consumption, body mass index, systolic blood pressure, triglyceride, total cholesterol and high-density lipoprotein cholesterol, diabetes, and cardiovascular disease; data not shown). Table 3 shows the mean and standard deviations for fibrinogen levels by genotype for each of the 4 SNPs.
We estimated the association of the 4 SNPs by sex and smoking status separately but none of the SNPs showed a significantly different association between subgroups (supplemental Tables II and III) .
A combined risk alleles score summarizing the number of risk alleles was associated with a 15% increase in overall mean fibrinogen level comparing subjects with no risk allele (mean fibrinogen level, 2.81 g/L) to subjects with 6 or more risk alleles (mean fibrinogen level, 3.24 g/L). The genetic variants identified in our study explained Ͻ2% of the overall variance in plasma fibrinogen in all studies except one.
To investigate the validity of our findings, we sought replication of the 4 loci using WHGS data. Because WHGS did not genotype the identical SNPs as our 6 cohorts, the best proxy SNP was used for replication. For rs1800789, rs2522056, rs511154, and rs1539019, we used WHGS SNPs rs6056 (r 2 ϭ0.95; Pϭ8.04ϫ10 Ϫ39 ), rs1016988 (r 2 ϭ0.80; Pϭ1.24ϫ10 Ϫ12 ), rs684773 (r 2 ϭ1.0; Pϭ1.92ϫ10 Ϫ5 ), and rs1539019 (Pϭ2.89ϫ10 Ϫ4 ), respectively, as the proxy SNP. The direction of each association in WHGS was consistent with our findings.
In addition to our 4 genome-wide significant loci, 2 other loci demonstrated multiple-SNP hits with P values Ͻ5ϫ10 Ϫ7 : 1 on chromosome 2 (rs4251961, Pϭ3.5ϫ10 Ϫ7 ) and 1 on chromosome 14 (rs8017049, Pϭ5.6ϫ10 Ϫ7 ). When we examined the results for these 2 loci in the WHGS data, we found evidence for replication on chromosome 2 (rs4251961 in WHGS, Pϭ8.5ϫ10 Ϫ3 ).
Discussion
We identified 4 loci associated with circulating fibrinogen level through a meta-analysis of GWA data from 6 cohort studies comprising 22 096 subjects. We provide strong information of the previously reported associations with the FGB locus. Three of our findings are newly identified associations.
The most significant SNP in our study was rs1800789 which is located on the FGB gene. The FGB gene encodes the fibrinogen ß chain. A well-characterized SNP at this locus is rs1800787 (Ϫ148C/T), which resides 965 base pairs away from our top SNP (rs1800789) and is in high linkage disequilibrium with it (DЈϷ1.0, r 2 ϭ0.91). It is known that rs1800787 directly affects gene transcription in basal and interleukin (IL)-6 -stimulated conditions in luciferase expression studies. 21 Another well-characterized SNP in this region is rs1800790 (455G/A), which is also in strong linkage disequilibrium with rs1800787, is known to be related to plasma fibrinogen 22 and showed a strong association with fibrinogen levels in our study as well (Pϭ5.04ϫ10 Ϫ27 , supplemental Table I ).
The second locus is located 25 kb downstream from the IRF1 gene on chromosome 5. IRF1 is a member of the interferon regulatory transcription factor family and activates transcription of interferon ␣ and ß. IRF1 also functions as a transcription activator of genes induced by interferon ␣, ␤, and ␥. Direct effects of interferons on fibrinogen have not previously been described, but it is known that they play a role in the regulation of acute phase proteins. Notably, the SNP is only 31 kb from a SNP strongly associated with Crohn disease in a recent meta-analysis (rs2188962, PϽ2.32ϫ10 Ϫ18 ). 23 Individuals with inflammatory bowel disease, including Crohn disease, are at a 3-fold higher risk of venous thrombosis, 24 accounting for substantial morbidity and mortality in this group. 25 Furthermore, multiple studies have indicated significantly elevated levels of fibrinogen in inflammatory bowel disease patients. 26 This suggests that IRF1 or nearby genes may contribute to Crohn disease via a mechanism mediated through an increase in acute-phase responsiveness and fibrinogen levels.
The third locus on chromosome 3 is located in intron 1 of the PCCB gene. The PCCB gene is responsible for a particular step in the breakdown of the amino acids isoleucine, methionine, threonine, and valine. However, the available information about PCCB does not provide a strong hypothesis about the putative function of the gene in regulation of fibrinogen levels.
The fourth locus on chromosome 1 is located on the NLRP3 gene. The NLRP3 gene encodes a pyrin-like protein, which interacts with the apoptosis-associated speck-like protein PYCARD/ASC and is a member of the NALP3 inflammasome complex. 27 Activated NALP3 inflammasome drives processing of the proinflammatory cytokine pro-IL-1ß to IL-1ß. Recent data indicate that the NALP3 inflammasome can be activated by endogenous "danger signals" as well as compounds associated with pathogens and triggers an innate immune response. 28 The finding on chromosome 2 is located in the promoter region (1-kb upstream from the transcription start site) of the IL-1 receptor antagonist (IL-1RN) gene. Fibrinogen is an acute phase protein that is regulated by cytokines, mainly IL-1 and IL-6, whereas the IL-6-mediated transcription of the fibrinogen gene is inhibited by IL-1ß. 29 This region has formerly reported to be associated with fibrinogen levels; rs2232354, which is in high linkage disequilibrium with our top SNP, rs4251961, was associated with fibrinogen levels in an asymptomatic population. 30 Our findings were replicated in WHGS. Two of our 4 SNPs are reported by WHGS as genome-wide significant findings (rs6056 and rs1016988) and the other 2 have P values that suggest nonchance findings in a replication (rs684773 and rs1539019). These results provide further credibility that our newly identified loci are valid.
We examined evidence for the top 4 fibrinogen loci among gene-expression quantitative trait loci from recent GWA studies in human liver tissues 31 and lymphoblastoid cell lines. 32 In liver tissues, SNPs at the FGB locus were strongly associated with the expression of FGB (eg, rs4508864, PϽ1.20ϫ10 Ϫ8 ) as well as with other translocated mRNAs. Likewise, we observed that several SNPs in the region of the IRF1 locus were strongly associated with the expression of nearby genes (including IRF1, LOC441108, and SLC22A5) in both liver tissues and lymphoblastoid cell lines (eg, rs2070729, Pϭ4.9ϫ10 Ϫ10 for expression of the IRF1 gene). These results from independent GWA studies strongly suggest a functional basis for the observed associations in the FGB and IRF1 loci.
Although heritability estimates for circulating fibrinogen are substantial, the genetic variants identified in our study explain only a small part of the overall variance. Therefore, our SNPs probably have limited value in prediction of cardiovascular disease. Rare variants, common variants with smaller effects, or variants which interact with other genetic and environmental factors may explain the remaining variation in plasma fibrinogen levels. Fibrinogen was measured independently in the 6 cohorts. Though methods for measuring fibrinogen concentration were not standardized, they were all based on the Clauss method or another clotting assay, except for KORA which used nephelometry. Nonetheless, the effect estimates for the top SNPs were comparable between KORA and other studies.
Contributing studies used different genotyping platforms with different groups of SNPs. To enable the meta-analysis, each study imputed Ϸ2.5 million SNPs in HapMap CEU samples. Imputation has previously been shown to be accurate and to increase the power. The power, of course, would have been higher if all SNPs were genotyped in all studies.
In conclusion, we have identified 4 loci associated with fibrinogen levels through meta-analysis of GWA data from 6 cohort studies comprising 22 096 subjects. All 4 loci replicated in a seventh study. In addition, we replicated 1 of the 2 other loci, which showed that a close-to-significant association in our meta-analysis and is biologically plausible. Three of our findings (IRF1, PCCB, and NLRP3) represent newly identified associations. Among the genes in the novel loci implicated in our study are those that encode proteins playing a role in inflammation representing interesting targets for further research into biological pathways involved in cardiovascular disease and other chronic inflammatory conditions. 
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